3D Bioprinted Human Tissue Market

Market CAGR for 3D Bioprinted Human Tissue is driven by the increasing use of 3D bioprinting in the pharmaceutical and cosmetic industries. 3D bioprinting facilitates the creation of intricate 3D structures, which pose challenges when using traditional manufacturing methods. This advancement has opened avenues for producing complex drug compounds and formulations, along with cosmetic items like artificial skin, hair follicles, and other tissues. For example, Chinese startup Triastek secured $15 million in Series A funding in December 2020 to accelerate the development of its 3D-printed pharmaceuticals.

The funding round, organized by fund management firm Dalton Venture, saw participation from Yunqi Partners and Shanghai Tofflon Science and Technology Chairman Zheng Xiaodong. Triastek intends to utilize the investment to establish a large-scale production line, conduct further research and development on its 3D-printed medications, and pursue registration applications in China and the U.S.

The market growth is expected to be driven by the increasing trend of product innovation and collaborations funded by both key market players and government agencies. In November 2022, as part of Northrop Grumman's 18th Commercial Resupply Services (NG-18) mission, an upgraded version of Redwire Space's BioFabrication Facility (BFF) was launched. This 3D bioprinter is capable of printing human tissue and is sponsored by the ISS National Laboratory. The project aims to pave the way for in-space bioprinting of tissues to assist patients on Earth, demonstrating how such product innovations contribute to market growth.

As a result, it is anticipated that throughout the projection period, demand for the 3D Bioprinted Human Tissue Market will increase due to the increasing use of 3D bioprinting in the pharmaceutical and cosmetic industries. Thus, driving the revenue of the 3D Bioprinted Human Tissue Market.

Regulatory support and frameworks are crucial for the advancement of the Global 3D Bioprinted Human Tissue Market Industry. Governments are increasingly recognizing the potential of bioprinting technologies and are establishing guidelines to facilitate their development and commercialization. This regulatory clarity not only instills confidence among investors but also encourages innovation within the sector. By providing a structured pathway for approval and market entry, regulatory bodies help streamline the process for bioprinted products, thereby enhancing their accessibility and adoption in clinical settings. Such support is likely to contribute to the market's growth in the foreseeable future.

The Global 3D Bioprinted Human Tissue Market Industry experiences a notable increase in demand for organ transplants, driven by a growing population and rising incidences of chronic diseases. As of 2024, the market is valued at approximately 3.22 USD Billion, reflecting the urgent need for innovative solutions to address organ shortages. Bioprinting technology offers a promising avenue for creating functional tissues and organs, potentially alleviating the burden on transplant waiting lists. This demand is projected to escalate further, contributing to the anticipated growth of the market, which is expected to reach 8.15 USD Billion by 2035.

The Global 3D Bioprinted Human Tissue Market Industry benefits from the growing applications of bioprinted tissues in drug testing and development. Traditional drug testing methods often rely on animal models, which may not accurately predict human responses. Bioprinted tissues offer a more reliable alternative, enabling researchers to conduct more relevant and ethical testing. This shift towards human-relevant models is gaining traction among pharmaceutical companies, which are increasingly adopting bioprinted tissues for preclinical testing. As the demand for effective drug testing solutions rises, the market is poised for significant growth, further solidifying its role in the pharmaceutical industry.

Technological advancements play a pivotal role in the expansion of the Global 3D Bioprinted Human Tissue Market Industry. Innovations in bioprinting techniques, such as the development of more sophisticated bioinks and improved printing resolutions, enhance the quality and functionality of bioprinted tissues. These advancements not only improve the viability of printed tissues but also expand their applications in drug testing and regenerative medicine. As a result, the market is projected to grow at a compound annual growth rate of 8.81% from 2025 to 2035, indicating a robust trajectory fueled by continuous technological evolution.

The Global 3D Bioprinted Human Tissue Market Industry is witnessing increased investment in regenerative medicine, as stakeholders recognize the potential of bioprinting technologies. Governments and private entities are allocating substantial funds to research and development initiatives aimed at advancing bioprinting capabilities. This influx of capital not only accelerates innovation but also fosters collaborations between academic institutions and industry players. Such partnerships are essential for translating research breakthroughs into practical applications, thereby enhancing the market's growth prospects. The focus on regenerative medicine is likely to drive the market's expansion in the coming years.

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The anticipated expansion of the 3D Bioprinted Human Tissue market in North America can be attributed to several key factors. Several global 3D bioprinting solution providers are expanding their footprint in the North American market to bolster their market presence. In July 2022, Ohio State University in the United States partnered with Nexxt Spine, LLC, to launch a clinical trial. This trial aims to assess and compare radiographic and clinical outcomes in patients undergoing combined interbody/posterolateral lumbar fusion procedures.

These procedures will utilize either the Nexxt Matrixx 3D-printed titanium cage or the Honour poly-ether-ether-ketone cage supplemented with pedicle screw instrumentation. Such partnerships and collaborations are anticipated to stimulate market growth.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.

Figure 2: 3D Bioprinted Human Tissue Market Share By Region 2023 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe's 3D Bioprinted Human Tissue Market accounts for the second-largest market share as Organ shortage remains a significant global challenge, including within Europe. 3D bioprinting presents a promising avenue by offering an alternative to conventional organ transplantation. Spain boasted the highest organ transplant rate in 2023, reaching 112.4 transplants per million population. This marked an increase of approximately 13 compared to 2021, representing the largest rate surge across European nations. Following Spain, Belgium held the second-highest rate in 2023, with 81.8 transplants per million. In 2021, Spain also led Europe with a kidney transplant rate of 63.2 per million population.

Furthermore, Spain recorded around 23 liver transplants per million in 2021, ranking fourth in Europe, surpassed only by Croatia, Italy, and Belgium. Although fully functional 3D bio-printed organs for transplantation are still in the early development stages, advances in tissue engineering are laying the groundwork for their eventual production. Further, the German 3D Bioprinted Human Tissue Market held the largest market share, and the UK 3D Bioprinted Human Tissue Market was the fastest-growing market in the European region.

The Asia-Pacific 3D Bioprinted Human Tissue Market is expected to grow at the fastest CAGR from 2025 to 2034. As per the Indian Brand Equity Foundation, the healthcare sector emerges as one of India's fastest-growing industries, projected to expand threefold to INR 8.6 trillion (USD 133.44 billion) by 2023. In the recent budget, India allocated 1.2% of its GDP to public healthcare expenditure, with plans to increase it to 2.5% of GDP by 2025. Such healthcare trends are poised to substantially drive market growth within the country. Numerous Indian startups are gaining traction by introducing innovative bioprinting solutions.

For example, Biop, founded by students from BITS Pilani and Goa, aims to revolutionize medical research by developing equipment and technology for 3D bioprinting. Their product allows for the creation of human tissues with a single click, utilizing sensors, actuators, and UV technology to regulate the bioprinting process. Collaborating with prestigious institutions like MIT and Harvard, the company is spearheading advancements in the field. The burgeoning startup ecosystem, coupled with the rising elderly population and incidence of cancer cases, are significant drivers expected to propel market growth in the foreseeable future.

Moreover, China’s 3D Bioprinted Human Tissue Market held the largest market share, and the Indian 3D Bioprinted Human Tissue Market was the fastest-growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development to expand their product lines, which will help the 3D Bioprinted Human Tissue market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the 3D Bioprinted Human Tissue industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global 3D Bioprinted Human Tissue industry to benefit clients and increase the market sector. In recent years, the 3D Bioprinted Human Tissue industry has offered some of the most significant advantages to the healthcare sector.

Major players in the 3D Bioprinted Human Tissue Market, including 3D Bioprinting Solutions, Allevi, Cellink Global, Cyfuse Biomedical K.K., EnvisionTEC, Inc., Inventia Life Science PTY LTD, Organovo Holdings, Inc., Poietis, Regemat 3D S.L., Vivax Bio, LLC are attempting to increase market demand by investing in research and development operations.

In 2021, Allevi joined the 3D Systems family as part of the company's strategic expansion into advanced bioprinting and regenerative medicine. The mission is to simplify the process of designing and engineering 3D tissues. The 3D bioprinters and bioinks provided by Allevi are utilized by prominent researchers globally to tackle humanity's most challenging issues, including disease treatment, drug testing, organ shortage mitigation, and life-oriented construction. Allevi by 3D Systems develops tools for designing and engineering living structures. Its desktop 3D bioprinters are renowned for their versatility, power, and user-friendliness, making them the preferred choice in numerous labs worldwide.

The community of users continually inspires the company, engaging in groundbreaking research on its platform.

Organovo Holdings, Inc. utilizes its 3D tissue technologies to create human models of inflammatory bowel disease (IBD), aiming to understand, invent, and develop effective drug therapies for ulcerative colitis and Crohn’s disease. The drugs discovered through this method are believed to have a higher likelihood of demonstrating benefits in clinical trials. Organovo's lead therapeutic molecule, FXR314, has shown promise in treating ulcerative colitis in the company's disease models and extensive preclinical testing.

In initial clinical trials, FXR314 has shown potential as a best-in-class FXR agonist, administered orally with high potency, safety, and tolerability, potentially avoiding dose-limiting toxicity issues observed in other FXR-targeted compounds. FDA authorization has been obtained for a Phase 2 trial of FXR314 in ulcerative colitis. Organovo plans to explore FXR314 for treating other inflammatory bowel diseases, including Crohn’s disease, as well as liver diseases, such as non-alcoholic steatohepatitis (NASH) and Primary Biliary Cholangitis. The company anticipates that FXR314 will have a broadening range of therapeutic applications as knowledge and scientific understanding continue to advance.